Drugs / SK Antithrombin III
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00846274 | Oct → Dec 2008 | — | SK Chemicals Co., Ltd. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK Antithrombin III | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00846274 ↗ |
| Known as | ATIII | “To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed” NCT00846274 ↗ |
| Known as | SKATIII | “To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed” NCT00846274 ↗ |
| Route | Intravenous | “100 U/kg IV for 20 minutes” PMID 24094463 ↗ Oct 2013 |